Upcoming Events

Date Event
June 7, 2021
Embargo will be lifted by Asco on abstract title and time of presentation on April 28, 2021.

Oral Presentation Details:

Title: "COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies"

Abstract: 2504

Session: Developmental Therapeutics—Immunotherapy

Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT

The abstract will be made available by ASCO on May 19, 2021, at 5:00 PM EDT on

The presentation will be made available on Compugen's website at following the conclusion of the presentation.

July 21, 2022

In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.

September 20, 2022 09:45 AM ET
Compugen participation at Fierce Biotech Summit


  • Yaron Turpaz, Senior Vice President and Senior Advisor, Computational Discovery
Panel: Leverage AI and ML to Advance Discovery and Accelerate Drug Development
September 29, 2022
Compugen participation at Immuno UK


  • Eran Ophir, Senior Vice President, Research and Drug Discovery Compugen

Presentation track: Discovery & Development: Intratumoral Immunotherapies & Antibody Therapies
Presentation title: Potential of PVRIG and TIGIT blockade in addressing immunotherapy resistance
Panel Discussion: Combinatorial Strategies in Immuno-Oncology